The Delhi High Court directed Dr Reddy’s Laboratories to stop selling or expanding its diabetes drug “Olymviq,” citing phonetic similarity with Novo Nordisk’s “Ozempic.” Justice Jyoti Singh noted such similarity in pharma crosses an unacceptable threshold, indicating prima facie trademark infringement.
